# Running the pre-launch marketing compliance check
A single slide killed a launch. A mock oncology brand team dropped a claim into a sales aid: "the first therapy to reverse tumor progression." One word, "reverse," was not in the FDA-approved label. In a real MLR review, that asset gets stopped cold, the launch date slips, and the medical reviewer starts asking why nobody caught it three weeks earlier. This lesson walks you through that catch, and the whole workflow behind it.
MLR stands for medical-legal-regulatory review: the mandatory internal approval process every piece of promotional material passes through before it reaches a doctor, patient, or payer. Three reviewers, three lenses:
In the US, the relevant authority is the FDA's Office of Prescription Drug Promotion (OPDP) for drugs and the FDA Center for Devices and Radiological Health (CDRH) for medical devices. In Europe, promotion is governed by the EMA (European Medicines Agency) framework plus national rules, and industry self-regulation runs through bodies like the ABPI in the UK and
No asset ships without an MLR sign-off. Not a tweet, not a booth banner, not a leave-behind.
Most pre-launch failures fall into three buckets. Learn to spot these fast.
An indication is the specific condition a product is FDA- or EMA-approved to treat, written into the label (also called the prescribing information or PI). Promoting any use outside that label is off-label promotion, and it is illegal in both the US and EU.
Concrete example: a drug approved for "moderate to severe plaque psoriasis in adults" cannot be marketed for pediatric patients, for mild psoriasis, or for psoriatic arthritis, even if trials are underway. The claim "reverse tumor progression" fails here too if the label only supports "delayed progression."
Off-label promotion has driven some of the largest pharma settlements in history under the US False Claims Act. This is not a paperwork risk. It is a criminal and civil exposure.
Fair balance is the legal requirement that promotional material present risk information with the same prominence as benefit information. If your headline screams efficacy in 40-point font and the side effects hide in 6-point footnote gray, you have failed fair balance.
The rule traces to the US Federal Food, Drug, and Cosmetic Act and FDA regulation 21 CFR 202.1. The FDA's guidance on prescription drug advertising lays out the mechanics in plain language.
Practical test: cover the benefit claims with your hand. Can the reader still find the important risks easily? If not, rebalance.
You cannot promote a product before it is approved. Period. Building buzz for a drug still under FDA review is pre-approval promotion, and it is prohibited.
The gray zone is disease-state awareness and coming soon messaging. A campaign that educates about a disease without naming the unapproved product may be allowed. The moment you tie the awareness to your specific pipelinepipelineAll active sales opportunities across the stages of the sales process, together with their combined potential value and probability of closing.View full definition → asset with a benefit implication, you have crossed into premature promotion.
Mock example: "A new era in migraine prevention is coming, ask about DrugX" before DrugX approval. Illegal. "Chronic migraine affects millions and is undertreated" with no product tie? Generally permissible as disease awareness, still subject to review.
Here is the review sequence on our mock launch: a fictional injectable device-drug combination for type 2 diabetes we will call "GlucoPen."
Before reviewing a single asset, pull the source documents:
Annotation means each claim in the piece carries a footnote pointing to the exact study, page, and figure that supports it. No annotation, no review. This is non-negotiable and the fastest way to catch fabricated or overstated claims.
Go line by line. For GlucoPen's sales aid:
| Claim | Supported by label? | Verdict |
|---|---|---|
| "Lowers A1C by up to 1.5%" | Yes, matches trial primary endpoint | Pass |
| "Once-weekly dosing" | Yes, in dosing section | Pass |
| "The safest option for diabetics" | No comparative superiority data | Fail |
| "Reverses insulin resistance" | Not in label | Fail |
"Safest" is a comparative claim, an assertion that your product beats competitors. Comparative claims require head-to-head clinical data. Marketing opinion does not count. Without a trial directly comparing GlucoPen to alternatives, strike it.
Check that the Important Safety Information (ISI), the mandatory risk summary, appears with adequate prominence. For an injectable, that includes injection-site reactions, hypoglycemia risk, and any boxed warning. If the ISI is buried on the back page while benefits fill the front, the piece fails.
Where and when does this ship? A pre-launch teaser going out before approval is premature promotion. A social post without a mechanism to display the ISI (a common failure on character-limited platforms) fails fair balance by construction.
Every reviewer signs. The approved version gets a unique ID and expiration date. Claims expire when data changes or the label updates. Shipping an expired asset is its own violation.
The single biggest structural difference: direct-to-consumer (DTC) advertising of prescription drugs is legal in only two developed countries, the United States and New Zealand. In the EU, DTC promotion of prescription-only medicines to the public is banned. You can run disease-awareness campaigns and promote to healthcare professionals, but you cannot advertise the prescription product itself to patients.
This means a US TV commercial for GlucoPen is legal (with full ISI read-out and fair balance). The same ad is illegal across the EU. Your compliance check must be geography-aware from the first draft.
Devices follow a different track. In the EU, medical devices fall under the Medical Device Regulation (MDR), and claims must align with the device's CE marking and intended purpose.
Knowledge check
1. In the opening example, a sales aid claimed a therapy could 'reverse tumor progression' when the approved label did not include the word 'reverse.' What core MLR failure does this illustrate?
2. A reviewer asks: 'Is every clinical claim in this brochure accurate and backed by the trial data?' Which lens of MLR review is this reviewer applying?
3. A drug is approved for 'moderate to severe plaque psoriasis in adults.' A marketing team wants to promote its use for a mild pediatric skin condition based on anecdotal physician feedback. Why is this prohibited?
4. Select ALL correct answers about how MLR review authorities and scope work.
Select all the correct answers.
5. Select ALL correct answers describing what each MLR lens is responsible for evaluating.
Select all the correct answers.
Fair balance is often argued as subjective. Regulators use rough proportionality as one signal. Here is a simple, defensible check a reviewer can apply to a printed sales aid.
Count the visual space (in square centimeters or as a percentage of the page) devoted to benefit messaging versus risk messaging.
Risk share = 30 / 210 = 14%
This is not a legal threshold (the FDA sets no fixed percentage), but a risk share this low is a red flag that invites reviewer scrutiny. A more balanced piece might land risk content nearer the benefit footprint, especially for products with serious warnings. Treat this as a screening heuristic, not a rule. The legal standard is whether the presentation is misleading, not whether a specific ratio is hit.
This lesson is educational and not legal advice. Always route real assets through qualified regulatory counsel and your internal MLR process.